Alkermes plc, of Dublin, reported total revenues of $248.7 million for the third quarter, which included sales of alcohol dependence drug Vivitrol (naltrexone for extended-release injectable suspension) totaling $79.9 million and sales of schizophrenia drug Aristada (aripiprazole lauroxil) totaling $36.1 million.